Glysit®
Dapagliflozin
SGLT2 inhibitors Metformin HCL
5mg,10mg
The SGLT2 is selectively expressed in the kidney with no expression detected in more than 70 other tissues including liver, skeletal muscle, adipose tissue, breast, bladder and brain. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation.
Info Sheet
Glysit® Plus
Dapagliflozin and Sitaglipin
Co-transporter 2 (SGLT2) inhibitors
10/50mg,10/100MG
Dapagliflozin mechanism of action is to inhibit the glucose transporter (SGLT2) in the renal tubule, thus reducing resorption of glucose by this transporter, with the consequent reduced blood glucose.Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus.
Info Sheet
Glysit® Met
Dapagliflozin and Metformin Hydrochloride
SGLT2 inhibitors Metformin HCL
5/500mg, 5/1000mg
Dapagliflozin mechanism of action is to inhibit the glucose transporter (SGLT2) in the renal tubule, thus reducing resorption of glucose by this transporter, with the consequent reduced blood glucose.Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia
Info Sheet